Communiqués Clover Biopharmaceuticals, Ltd.

Actions

2197

KYG2280A1076

Recherche biotechnologique et médicale

Marché Fermé - Hong Kong S.E. 10:08:36 21/09/2026			Varia. 5j.	Varia. 1 janv.
2,150 ^HKD	+1,65%		+12,57%	-8,12%

07/09	Clover Biopharmaceuticals annonce des données cliniques de Phase 2 positives pour ses candidats vaccins combinés respiratoires VRS + hMPV ± PIV3 chez les adultes âgés	CI
07/09	Les vaccins de Clover Biopharma contre les maladies respiratoires affichent des résultats prometteurs lors d'essais de phase II en Australie	MT

Communiqués

07/09	Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults	PR
25/03	Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults	PR
12/01	Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates	PR
20/10/25	Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances	PR
14/10/25	Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults	PR
17/06/25	Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates	PR
24/03/25	Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019	PR
28/10/24	Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY	PR
19/06/24	Clover Announces Positive Preliminary Phase Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults	AQ
18/06/24	Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults	PR
08/04/24	Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort	PR
29/12/23	Clover Announces Positive Phase ? Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)	AQ
13/12/23	Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate	PR
12/09/23	Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	GL
12/09/23	Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	AQ
11/07/23	Clover Provides Updates on Business and R&D Pipeline Development	GL
11/07/23	Clover Provides Updates on Business and R&D Pipeline Development	AQ
24/05/23	Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China	GL
24/05/23	Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China	AQ
29/03/23	Clover Biopharmaceuticals Announces Corporate Updates and Full Year 2022 Financial Results	AQ
29/03/23	Clover Announces Corporate Updates and Full Year 2022 Financial Results	GL
29/03/23	Clover Announces Corporate Updates and Full Year 2022 Financial Results	AQ
20/02/23	Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China	GL
15/02/23	Clover Biopharmaceuticals Launches COVID-19 Booster Vaccine in the People's Republic of China	AQ
14/02/23	UPDATE -- Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China	GL